First AD

Second AD

Coherus Rep Predicts How the Ophthalmology Biosimilars Space Will Develop

Coherus Rep Explains What Interchangeability Means in Ophthalmology vs Rheumatology

Coherus Rep Discusses Why Coherus Sought Interchangeability for Cimerli

Coherus Rep Previews the US Market Introduction of Adalimumab Biosimilars

Coherus Rep Shares Competition Strategy for Adalimumab, Pegfilgrastim Biosimilars

News

Oncology

Ophthalmology

Rheumatology

Gastroenterology

Paul Reider, chief commercial officer at Coherus Biosciences, previews the excitement surrounding the US adalimumab biosimilar space and why Coherus has decided not to pursue interchangeability for Yusimry.

Part 5 available now! 

Paul Reider, MBA, chief commercial officer at Coherus Biosciences, chronicles why Coherus got an interchangeable designation for its ophthalmology biosimilar, how it plans to set its adalimumab biosimilar apart from the rest, and when the pegfilgrastim market could see a competitor for Neulasta Onpro.

Coherus Rep Discusses Interchangeable Ophthalmology Biosimilar, Previews Onpro Competitor